Establishment Labs (NASDAQ:ESTA) Given New $86.00 Price Target at Needham & Company LLC

Establishment Labs (NASDAQ:ESTA) had its price target raised by Needham & Company LLC from $84.00 to $86.00 in a research note published on Tuesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the company. Canaccord Genuity Group lifted their price objective on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. BTIG Research upped their price objective on Establishment Labs from $81.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Citigroup raised their price objective on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. increased their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and an average target price of $79.14.

Establishment Labs Stock Performance

ESTA stock opened at $79.67 on Tuesday. The firm has a 50-day simple moving average of $70.99 and a two-hundred day simple moving average of $57.73. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -28.05 and a beta of 0.99. The company has a debt-to-equity ratio of 15.06, a quick ratio of 2.10 and a current ratio of 3.33. Establishment Labs has a one year low of $26.56 and a one year high of $79.90.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The company had revenue of $64.62 million for the quarter, compared to analyst estimates of $63.80 million. During the same period in the prior year, the company posted ($1.19) EPS. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, equities analysts forecast that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in Establishment Labs by 5.8% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock worth $261,000 after buying an additional 350 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Establishment Labs by 7.3% in the 4th quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock valued at $641,000 after buying an additional 600 shares in the last quarter. Swiss National Bank increased its stake in shares of Establishment Labs by 1.8% in the 4th quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after acquiring an additional 600 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs during the 4th quarter valued at about $47,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

More Establishment Labs News

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 beat on both EPS and revenue: ESTA reported a loss of ($0.09) vs. consensus ($0.22) and revenue of $64.62M, up 45% year-over-year — a surprise to the upside that likely lifted the stock. Zacks Q4 Revenue Beat
• Positive Sentiment: FY 2026 revenue guidance was updated to about $264.0M–$266.0M, slightly above the Street’s ~$263.2M consensus — supporting the view that top-line momentum continues. (Guidance detail from company release coverage.)
• Positive Sentiment: Analyst support: Needham raised its price target from $84 to $86 and maintained a Buy rating, providing additional buy-side validation. Tickerreport — Needham Raise
• Neutral Sentiment: Management commentary and detail available — the Q4 earnings call transcript and press release provide more context on growth drivers and margin trajectory; investors will watch the call for cadence on profitability and product uptake. Earnings Call Transcript Company Press Release
• Neutral Sentiment: Industry/peer context and previews continue to be published (comparisons and previews may influence positioning but are not immediate catalysts). Investing.com preview Company Comparison
• Negative Sentiment: Profitability remains a concern: the company still reported a negative net margin (~43%) and a deeply negative return on equity, underscoring that earnings are not yet sustainable and that dilution/financing risk remains. MarketBeat Earnings Summary

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.